eMed, which named Brady as its chief wellness officer earlier this year, gives patients access to GLP-1s, at-home blood testing and monthly clinical consultations
Tom Brady isn’t just the face of eMed; he now has skin in the game.
The Miami-based telehealth platform, which named the NFL legend as its chief wellness officer earlier this year, has raised $200 million in funding at a $2 billion-plus valuation, the company announced Thursday.
The round included lead investor Aon Consulting Inc., with participation from Brady, Palantir co-founder Joe Lonsdale, Chicago Cubs Chairman Tom Ricketts and eMed CEO Linda Yaccarino, among others.
eMed said the proceeds will advance its agentic AI platform, strengthen its balance sheet and support a new structure meant to help employers reduce healthcare costs.
“I believe eMed’s empathic agentic AI platform, combined with the strength of its people and partners, represents a true winning formula,” Brady said. “That conviction is why I’ve chosen to invest both my time as founding chief wellness officer and my capital in the company.”
eMed‘s platform gives patients access to weight loss medications like GLP-1s, at-home blood testing upon onboarding and monthly clinical consultations with required check-ins throughout.
The bigger play, however, is eMed’s corporate offering. The company says GLP-1 medications are the most requested workplace benefit, yet only one in five employers provides them. According to Sequoia’s 2026 Health and Wellbeing report, the cost and demand of weight loss medications have pushed coverage conversations to the top of the benefits agenda for 35% of employers.
At the same time, workers are increasingly expecting fitness and wellness benefits from employers. Among younger workers, 39% of Millennials and 35% of Gen Z say access to weight loss medications would improve their job satisfaction or productivity, according to a 2025 Employee Benefit News report.
